FromBio is showing strong performance. This is interpreted as the spotlight on a hair loss treatment made using adipose-derived stem cells following the government's announcement of eased regulations on stem cell therapy.
As of 10:44 AM on the 14th, FromBio is trading at 7,670 KRW, up 3.65% compared to the previous day.
According to industry sources, Kang Ki-yoon, a member of the National Assembly Health and Welfare Committee from the People Power Party, recently introduced a bill to amend the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act (ARMA) to expand the scope of advanced regenerative treatments. The core of the amendment is to allow advanced regenerative treatment procedures using stem cells, T cells, and natural killer (NK) cells to be paid for and received at domestic medical institutions.
According to the medical community, it is estimated that about 10,000 to 20,000 patients travel abroad annually, to countries like Japan, for immune cell and stem cell treatments. The cost of these treatments is known to reach up to 100 million KRW.
Many evaluations suggest that the amendment to ARMA will benefit not only patient treatment but also new drug development, as regenerative medical procedures for treatment purposes will be permitted, not just for research.
Meanwhile, FromBio, a company specializing in health functional foods, announced in May that it successfully demonstrated hair growth effects in preclinical studies of a hair loss treatment made using adipose-derived stem cells differentiated into mammary papilla cells.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
